Andrew Abaasa1, Gershim Asiki2, Matthew A Price3, Eugene Ruzagira4, Freddie Kibengo5, Ubaldo Bahemuka6, Patricia E Fast7, Anatoli Kamali8. 1. MRC/UVRI, Uganda Research Unit on AIDS, Entebbe, Uganda. Electronic address: Andrew.Abaasa@mrcuganda.org. 2. MRC/UVRI, Uganda Research Unit on AIDS, Entebbe, Uganda. Electronic address: gershim@gmail.com. 3. International AIDS Vaccine Initiative, New York, USA; University of California at San Francisco, Department of Epidemiology and Biostatistics, San Francisco, USA. Electronic address: MPrice@iavi.org. 4. MRC/UVRI, Uganda Research Unit on AIDS, Entebbe, Uganda. Electronic address: Eugene.Ruzagira@mrcuganda.org. 5. MRC/UVRI, Uganda Research Unit on AIDS, Entebbe, Uganda. Electronic address: Freddie.Kibengo@mrcuganda.org. 6. MRC/UVRI, Uganda Research Unit on AIDS, Entebbe, Uganda. Electronic address: Ubaldo.Bahemuka@mrcuganda.org. 7. International AIDS Vaccine Initiative, New York, USA. Electronic address: PFast@iavi.org. 8. MRC/UVRI, Uganda Research Unit on AIDS, Entebbe, Uganda. Electronic address: Anatoli.Kamali@mrcuganda.org.
Abstract
BACKGROUND: Clinical trial participants may differ from the source population due to the demands of trial participation and self-selection, inadvertent selection of a lower-risk group, or both. We investigated the HIV risk status of volunteers in a Simulated Vaccine Efficacy Trial (SiVET) nested within a prospective observational cohort of fisher folks in South Western Uganda. METHODS: Volunteers aged 18-49 years, at high risk for HIV from fishing communities in Masaka district were recruited into an observational cohort and followed quarterly. High risk was defined as a self-report, of at least one of the following in the past three months; sexually transmitted infections, unprotected sex with >1 partner or a new sexual partner, use of recreational drugs, weekly alcohol use, and/or frequent travel. Volunteers who had at least three months of follow-up in the observational cohort were consecutively enrolled in SiVET, administered Hepatitis B vaccine at months (0, 1, 6) and followed-up three days post vaccinations to mimic a vaccine trial schedule. HIV incidence over the next 12 months was compared between SiVET and the observational cohort studies. RESULTS: Between January 2012 and February 2013, 575 individuals were enrolled in the observational cohort, of whom 282 were enrolled in SiVET between July 2012 and February 2013. Despite similar pattern of reported risk behaviour in both studies, HIV incidence was higher in observational cohort, 11.4 cases/100 PYO [95% CI: 7.4-17.7] compared to 3.8 [95% CI: 2.0-7.0] in SiVET (p<0.01). SiVET volunteers tended to be men, having some education and longer-term residents, all factors that are also associated with lower HIV risk. CONCLUSION: We observed a lower HIV incidence in SiVET than in the observational cohort. The two populations differed significantly in demographics but not in reported risk. HIV incidence estimates from observational cohorts must be used with caution to estimate the trial study size.
BACKGROUND: Clinical trial participants may differ from the source population due to the demands of trial participation and self-selection, inadvertent selection of a lower-risk group, or both. We investigated the HIV risk status of volunteers in a Simulated Vaccine Efficacy Trial (SiVET) nested within a prospective observational cohort of fisher folks in South Western Uganda. METHODS: Volunteers aged 18-49 years, at high risk for HIV from fishing communities in Masaka district were recruited into an observational cohort and followed quarterly. High risk was defined as a self-report, of at least one of the following in the past three months; sexually transmitted infections, unprotected sex with >1 partner or a new sexual partner, use of recreational drugs, weekly alcohol use, and/or frequent travel. Volunteers who had at least three months of follow-up in the observational cohort were consecutively enrolled in SiVET, administered Hepatitis B vaccine at months (0, 1, 6) and followed-up three days post vaccinations to mimic a vaccine trial schedule. HIV incidence over the next 12 months was compared between SiVET and the observational cohort studies. RESULTS: Between January 2012 and February 2013, 575 individuals were enrolled in the observational cohort, of whom 282 were enrolled in SiVET between July 2012 and February 2013. Despite similar pattern of reported risk behaviour in both studies, HIV incidence was higher in observational cohort, 11.4 cases/100 PYO [95% CI: 7.4-17.7] compared to 3.8 [95% CI: 2.0-7.0] in SiVET (p<0.01). SiVET volunteers tended to be men, having some education and longer-term residents, all factors that are also associated with lower HIV risk. CONCLUSION: We observed a lower HIV incidence in SiVET than in the observational cohort. The two populations differed significantly in demographics but not in reported risk. HIV incidence estimates from observational cohorts must be used with caution to estimate the trial study size.
Authors: Eugene Ruzagira; Symon Wandiembe; Leonard Bufumbo; Jonathan Levin; Matthew A Price; Heiner Grosskurth; Anatoli Kamali Journal: Trop Med Int Health Date: 2009-01-15 Impact factor: 2.622
Authors: Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Sheena McCormack; Gita Ramjee; Anatoli Kamali; Helen Rees; Angela M Crook; Mitzy Gafos; Ute Jentsch; Robert Pool; Maureen Chisembele; Saidi Kapiga; Richard Mutemwa; Andrew Vallely; Thesla Palanee; Yuki Sookrajh; Charles J Lacey; Janet Darbyshire; Heiner Grosskurth; Albert Profy; Andrew Nunn; Richard Hayes; Jonathan Weber Journal: Lancet Date: 2010-09-17 Impact factor: 79.321
Authors: Andrew Nunn; Sheena McCormack; Angela M Crook; Robert Pool; Clare Rutterford; Richard Hayes Journal: Trials Date: 2009-10-27 Impact factor: 2.279
Authors: Judith Vandepitte; Justine Bukenya; Helen A Weiss; Susan Nakubulwa; Suzanna C Francis; Peter Hughes; Richard Hayes; Heiner Grosskurth Journal: Sex Transm Dis Date: 2011-04 Impact factor: 2.830
Authors: Andrew Abaasa; Gershim Asiki; Juliet Mpendo; Jonathan Levin; Janet Seeley; Leslie Nielsen; Ali Ssetaala; Annet Nanvubya; Jan De Bont; Pontiano Kaleebu; Anatoli Kamali Journal: BMC Res Notes Date: 2015-12-24
Authors: Zachary Arochi Kwena; Elizabeth A Bukusi; Janet M Turan; Lynae Darbes; Carey Farquhar; Catherine Makokha; Jared M Baeten Journal: Arch Sex Behav Date: 2022-03-25
Authors: Stephen Nash; Victoria Tittle; Andrew Abaasa; Richard E Sanya; Gershim Asiki; Christian Holm Hansen; Heiner Grosskurth; Saidi Kapiga; Chris Grundy Journal: Emerg Themes Epidemiol Date: 2018-08-13
Authors: Pholo Maenetje; Christina Lindan; Heeran Makkan; Candice M Chetty-Makkan; Mary H Latka; Salome Charalambous; Mandla Mlotshwa; Matshidiso Malefo; William Brumskine; Nancy K Hills; Matthew A Price; Vinodh Edward Journal: PLoS One Date: 2019-04-03 Impact factor: 3.240
Authors: Andrew Abaasa; Jim Todd; Stephen Nash; Yunia Mayanja; Pontiano Kaleebu; Patricia E Fast; Matt Price Journal: BMC Med Res Methodol Date: 2020-02-12 Impact factor: 4.615
Authors: Ubaldo Mushabe Bahemuka; Andrew Abaasa; Eugene Ruzagira; Christina Lindan; Matt A Price; Anatoli Kamali; Pat Fast Journal: PLoS One Date: 2019-01-14 Impact factor: 3.240
Authors: Andrew Abaasa; Jim Todd; Yunia Mayanja; Matt Price; Patricia E Fast; Pontiano Kaleebu; Stephen Nash Journal: Sci Rep Date: 2019-10-28 Impact factor: 4.379
Authors: Zachary Kwena; Sarah Nakamanya; Gertrude Nanyonjo; Elialilia Okello; Pat Fast; Ali Ssetaala; Bertha Oketch; Matt Price; Saidi Kapiga; Elizabeth Bukusi; Janet Seeley Journal: BMC Public Health Date: 2020-06-15 Impact factor: 3.295